ストックスクリーナーアプリを入手
6.20
3.73%
-0.24
アフターアワーズ：
6.20
前日終値:
$6.44
開ける：
$6.55
24時間の取引高:
7,061
Relative Volume:
0.00
時価総額：
$7.23M
収益：
$1,000
当期純損益:
$-11.39M
株価収益率:
-0.2018
EPS:
-30.7182
ネットキャッシュフロー:
$-7.26M
1週間 パフォーマンス:
-6.77%
1か月 パフォーマンス:
-21.42%
6か月 パフォーマンス:
-80.00%
1年 パフォーマンス:
-86.45%
1日の値動き範囲:
$6.20
$6.67
1週間の範囲:
$6.20
$7.28
52週間の値動き範囲:
$3.1829
$71.50
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
名前
Ernexa Therapeutics Inc
セクター
電話
(617) 798-6700
住所
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
6.20 | 7.51M | 1,000 | -11.39M | -7.26M | -30.72 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ernexa Therapeutics Inc (ERNA) 最新ニュース
Eterna Therapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosures - TipRanks
Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) investors back directors, auditor and 2026 equity plan - Stock Titan
ERNA Q3 2023 Earnings: Reported Loss per Share of -$1.03, Stock Rises $1.37Revenue Growth Outlook - dars.gov.et
ERNA stock shoots up 140% in a month: Here's what you should know - MSN
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Ernexa Therapeutics Warrants (ERNAW) Hold Steady at $0.06 – A Waiting Game for CatalystsUnusual Call Volume - dars.gov.et
Price to sales forward of Ernexa Therapeutics Inc. – BOATS:ERNAW - TradingView
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Eterna Therapeutics announces finance leadership transition and search - TipRanks
Sandra Gurrola to Resign as Ernexa's Senior VP of Finance, Effective July 3, 2026 - TradingView
Ernexa Therapeutics (ERNA) finance SVP resigns, will aid transition - Stock Titan
Ernexa Therapeutics Inc. Announces Resignation of Sandra Gurrola from Senior Vice President of Finance, Effective July 3, 2026 - marketscreener.com
Ernexa Therapeutics Surges 20.6%: Momentum Builds for ERNA Stock After BreakoutVolume Nodes - dars.gov.et
Ernexa Therapeutics Launches CEO Corner Platform to Highlight Scientific Strategy and Mission - Quiver Quantitative
Ernexa uses video to explain its cell-therapy strategy and patient mission - Stock Titan
ERNA Should I Buy - Intellectia AI
ERNA Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Ernexa Therapeutics Positioned to Become A Clinical-Stage Biotechnology Company as ERNA-101 on Track for Planned Third Quarter 2026 IND Submission and First-In-Human Study - marketscreener.com
Ernexa advances cell therapy toward clinical trial this year By Investing.com - Investing.com Canada
Ernexa Therapeutics Advances ERNA-101 Towards First-in-Human Trials as Manufacturing and Regulatory Milestones are Achieved - Quiver Quantitative
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study - Yahoo Finance
Ernexa Therapeutics Warrants (ERNAW) Dip Further, Approaching Key Support at $0.10Virgin POC - newsline.com
What It's Like To Advance A Cell Therapy Through The Japan Entry Acceleration Program - Clinical Leader
ERNA Q3 2023 Earnings: Pre-Revenue Biotech Reports Wider Loss as Stock DeclinesSubscription Growth Report - newsline.com
Ernexa Therapeutics (ERNA) Drops Over 6%: Key Support Levels in FocusFibonacci Fan - newsline.com
Number of shareholders of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics stock climbs on breakthrough preclinical data - MSN
Ernexa highlights ERNA-101's potential to improve ovarian cancer treatment with scalable, off-the-shelf cell therapy. - Pluang
Ernexa Therapeutics Highlights Innovative Cell Therapy Approaches for Ovarian Cancer in Virtual Investor KOL Connect Segment - Quiver Quantitative
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, - GlobeNewswire
ERNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ERNA Q3 2023 Earnings: Pre-Revenue Biotech Reports Wider Loss, Shares Tumble 12%EBITDA Analysis - newsline.com
ERNAErnexa Therapeutics Inc Revenue Breakdown - Finviz
Ernexa Therapeutics Warrants (ERNAW) Slide Over 20% as Key Support NearsPositive Gamma - The Legal Advocate
Ernexa Therapeutics Warrants Drop 21.76%: Warrants Plunge Below Key Support LevelMomentum ETF - The Legal Advocate
Ernexa Therapeutics (ERNA) Faces Sharp Sell-Off, Testing Key Support at $10.20Elliott Wave Count - newsline.com
Ernexa Therapeutics (ERNA) Surges 4.31%: Key Levels and Technical OutlookFloat Adjusted Cap - The Legal Advocate
Ernexa Therapeutics Inc. (ERNA) Q3 2023 Earnings: Negative EPS as Company Advances PipelinePre-Earnings Drift - The Legal Advocate
Number of shareholders of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Warrants (ERNAW) Slide Marginally to $0.15, Testing Key Support ZoneInverse ETF Flow - thelegaladvocate.com
Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing - Investing.com
Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing By Investing.com - Investing.com Australia
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development - The Globe and Mail
Ernexa Therapeutics Successfully Completes Key - GlobeNewswire
Ernexa stock is jumping today: What's going on? - MSN
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - bioinformant.com
Ernexa Therapeutics (ERNA) Q3 2023 Earnings: Net loss of $1.03 per share highlights ongoing clinical investment; stock declines 3.77%Annual Report - newsline.com
Ernexa Therapeutics Inc (ERNA) 財務データ
収益
当期純利益
現金流量
EPS
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):